Crystalline Polyether-Ester-Urethane Bioactive Liner
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical treatments for vaginal and esophageal fungal infections, as well as vascular restenosis, face challenges such as drug toxicity, uncontrolled leakage, and unpredictable bioavailability due to the lack of effective, bioadhesive, and resilient drug delivery systems that can withstand shear stresses and aqueous environments.
Innovation Solution
Development of absorbable, crystalline polyether-ester-urethane-based compositions that form a bioactive, adhering liner upon contact with the luminal surface, incorporating bioactive agents like antifungal and antibacterial agents, which are designed to provide controlled release and resistance to deformation under shear forces, using a specific synthesis method involving polyalkylene glycol, cyclic monomers, and diisocyanates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional polyurethane materials are used for drug delivery, then they provide good mechanical properties and blood compatibility, but they generate toxic aromatic diamines upon degradation and undergo chain degradation due to oxidation
Solution Approach 1:
The patent changes the chemical parameters of the polyurethane by using aliphatic diisocyanates instead of aromatic diisocyanates, and by incorporating hydrolytically unstable urethane linkages that degrade to non-toxic products. This parameter change eliminates the formation of toxic aromatic diamines while maintaining the desired mechanical and biocompatible properties.
Solution Approach 2:
The patent creates a composite material system combining polyether segments with ester-urethane linkages. This composite structure provides both the biocompatibility and mechanical properties of polyurethane while the ester-urethane component degrades to non-toxic products, avoiding the toxicity issue of conventional aromatic polyurethanes.
2Strength
If amorphous hydroswellable coatings are used for luminal liner applications, then they provide good adhesion and flexibility, but they undergo excessive deformation and creep under shear stresses
Solution Approach 1:
The patent utilizes the phase transition properties of crystalline materials by incorporating semi-crystalline polyether-ester-urethane segments. The crystalline regions provide structural stability and resistance to deformation under shear stress, while the amorphous regions maintain adhesion and flexibility. This phase transition approach resolves the contradiction between adhesion and deformation resistance.
Solution Approach 2:
The patent creates a composite structure with both crystalline and amorphous phases within the polymeric matrix. The crystalline domains provide mechanical strength and resistance to creep, while the amorphous domains provide adhesion and flexibility. This composite material approach simultaneously achieves both adhesion and stability under shear stress.
3Reliability
If drug delivery systems are designed for controlled release, then they improve bioavailability and reduce toxicity, but they require complex formulation systems that are difficult to manufacture
Solution Approach 1:
The patent designs a polymeric material that performs multiple functions: it provides structural support as a luminal liner, enables controlled drug release through its degradation profile, and ensures biocompatibility. This multi-functional material eliminates the need for separate complex formulation systems, simplifying manufacturing while achieving controlled release and improved bioavailability.
Solution Approach 2:
The patent controls the degradation rate and drug release kinetics by adjusting the molecular weight, composition ratio of crystalline to amorphous phases, and crosslinking density of the polyether-ester-urethane. These parameter changes enable tailored controlled release profiles without requiring complex formulation systems, making the device easier to manufacture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline polyether-ester-urethane compositions offer a resilient, bioadhesive, and controlled drug release system that effectively treats vaginal and esophageal infections and prevents vascular restenosis by maintaining bioavailability and stability, reducing the risk of drug toxicity and leakage.
Implementation Method 1
absorbable crystalline polyether-ester-urethane-based compositions that can be delivered to the luminal wall of a body cavity or conduit of the gastrointestinal tract, urinogenital or vascular systems to form a bioactive, adhering liner upon contacting the respective wet luminal surface
Data Source
AI summary
Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.